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September 2010662 Guzzo et altightly controlled. Third, there may be an obvious disparity
in the duration and type of anticoagulation as well as
endovascular treatments offered by the many endovascular
interventionalists prior to patients coming to our care.
Fourth, we are hampered by a relatively short follow-up
interval. And finally, even though we have the largest
prospective database with regard to TOS, wemay only have
outcomes from which we can demonstrate clinical observa-
tions but understandably lack the statistical power to make
definitive claims that a well-designed, randomized, con-
trolled trial affords.
But the very nature of this variability of our patients’
clinical picture and initial treatment may in fact strengthen
the notion that this treatment, be it thombolysis or simple
anticoagulation, has little impact on obtaining a successful
outcome following operative decompression. In addition,
it does not seem that in a relatively young and active patient
population, evaluation and stratification for cardiovascular
risk factors and comorbidities would confound data gener-
ated to compare treatments in a venous compression phe-
nomena. The short follow-up interval may not have large
clinical impact, as we have had very few overall patients lost
to follow-up (6% of total cohort), and we have had no
patients reocclude at distant time points in our care among
the 103 treated. What our retrospective data do suggest is
that a prospective, randomized controlled trial should be
performed to validate what could be a meaningful change
in the current treatment paradigm for subacute and chronic
effort thrombosis patients.
CONCLUSIONS
Preoperative endovascular therapy with thombolysis
and possible venoplasty offered no overall benefit in pa-
tients with subacute and chronic effort thrombosis, or
Paget-Schroetter syndrome. In this series, 41% of patients
underwent endovascular intervention prior to operative
decompression with FRRS, but showed no improvement in
outcome as determined by vein patency on postoperative
venography, follow-up duplex ultrasound, and symptom res-
olution versus anticoagulation alone. As such, the optimal
treatment algorithm may merely be routine anticoagulation
for all subacute and chronic effort thrombosis patients prior
to FRRS followed by venography with venoplasty as
needed. Liberal use of anticoagulation for those who have
had venoplasty and have a vein occlusion also plays an
important role in the vein remaining patent. Overall, 91%
of patients in each group have patent subclavian veins by
duplex scan and are back to their previous active lifestyle.
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Dr L. Richard Sprouse (Chattanooga, Tenn). Thank you.
First of all, I would like to thank the authors for providing me
with this manuscript before the meeting. I haven’t noticed any
major changes compared to the original abstract that was sub-
mitted to the Southern Association for Vascular Surgery, and I
would like to congratulate Dr Guzzo on an outstanding presen-Dr Guzzo and colleagues present a retrospective analysis of
more than 100 patients presenting with axillosubclavian venous
thrombosis related to venous thoracic outlet syndrome. The pur-
pose of the paper was to compare the effectiveness of thrombolysis
and PTA with anticoagulation alone in those patients undergoing
FRRS to preserve subclavian vein patency. The authors conclude
that preoperative thrombolysis doesn’t improve subclavian vein
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Volume 52, Number 3 Guzzo et al 663patency and argue that routine anti-coagulation provides accept-
able results and may lead to significant cost savings. Based on
previous reports from their institution and others, I adopted an
aggressive approach over the past several years in managing pa-
tients with effort thrombosis. All patients presenting with subcla-
vian vein thrombosis for TOS at my institution undergo immediate
thrombolysis, percutaneous thrombectomy, and angioplasty fol-
lowed by early transaxillary first rib resection.
The severity of symptoms in the patients presented by Dr
Guzzo was not clearly stated in the manuscript, but many of the
patients I encounter with venous TOS present with debilitating
symptoms, and early intervention in these patients provides signif-
icant symptomatic relief and facilitates a quick recovery. Many of
the patients in the current study also underwent early intervention
with thrombolysis; however, it is not clearly stated in the manu-
script why some patients were treated only with anti-coagulation.
In addition, many of the patients had undergone interventions at
other facilities prior to presentation but the manuscript does not
provide the details of these procedures and does not state which
patients received prior treatment. Although the demographics of
the two study groups described by the authors appear similar,
comparing the groups in regards to the patency of the subclavian
vein appears hazardous withoutmore information regarding which
patients received which intervention during what time period and
for what reason. I have several questions for the authors:
1. Can you describe what defined a patient as being symptomatic
at the time of presentation?
2. Do you have an idea of the severity of the symptoms and, if so,
how did this influence the initial treatment recommendations?
3. Can you provide the details regarding the initial venoplasty
procedure? What was the typical ballon size? Did you use
cutting balloons or any other local therapies? And did any of
the patients have percutaneous thrombectomy in addition to
thrombolysis?
4. You stated that 45 patients had thrombolysis alone or throm-
bolyis  PTA prior to FRSS. Were all of these procedures
successful in restoring patency of the vein? And of the seven
occlusions that occurred postoperatively, how many of these
only had thrombolysis at the initial procedure?
5. Finally, you report that despite the failure to cross many of these
lesions and reopen the vein, more than 80% of the occluded
subclavian veins had recanalized and were patent on follow-up
ultrasound, and the patients were asymptomatic. Do you think
this argues for a more selective approach to performing the
2-week venogram and potentially eliminating it as an additional
cost-saving measure?
Again, I would like to congratulate the authors on an out-
standing presentation and I am honored that the Southern Asso-
ciation for Vascular Surgery invited me to discuss this paper.
Dr James L. Guzzo (Baltimore, Md). Thank you very much;
those are all excellent questions. I will try to go down the list. As far
as defining symptoms, since the majority of the patients receive
initial evaluation at outside hospitals, the best we have is our first
clinic evaluation. We did go through all 100 patients’ clinic charts;sometimes when we see them it is a couple of weeks after that initial
event, and more rarely, a few months. Their symptoms run the
gamut, so as far as pinning them down and saying, “Did you have
an acute limb?” that obviously came back as “No.” But someone
with more severe symptoms in the dominant limb is oftentimes
more alarming to the patient and even to the treating physician
(more than something that happens in the leg), and this perception
may lead to the decision to perform thombolysis. Because such a
vast number were done at an outside hospital, it becomes a
potential study weakness because they weren’t all treated at our
institution. We cannot make that definitive claim where yes, the
arm looked terrible, they really deserve lytics, or yes, it is not so
bad, raise your arm and go home on Lovenox and you will feel fine
in a day.
As far as balloon size, typically we use an 8, 10, or 12 for serial
dilations almost routinely. We have even gone up to a 14 to 16 on
rare occasions. The venograms are performed in greater than 95%
by our staff in the vascular division. Those are the ones that I was
lucky to be involved with, so a majority used that series of balloons
in those with angiographic evidence of a greater than 50% stenosis
of the subclavian vein. Nobody was thrombectomized nor were
open or percutaneous/Angiojet-type systems utilized; nobody
received stents either. Outside of this cohort, since May 2009, we
have had several people referred who have been stented by outside
facilities prior to referral for rib resection, and they do terribly.
They are all occluded, and following first rib resection and scale-
nectomy, we still can’t get them open. Their outcomes are still in
evolution, and hopefully we will report on them at a later date, as
we think they have done poorly enough that that warrants some
investigation as well.
As far as patency after those procedures at an outside hospital,
we can only comment if we are lucky enough to get the operative
reports, as they come from all over the country. Unfortunately, I
don’t have numbers to say yes, that lytic therapy rendered their
subclavian vein patent or their balloon angioplasty rendered them
patent; however, anecdotally we do have a number of people who
do get lysed prior to our initial evaluation before rib resection and
scalenectomy, and on duplex are thrombosed again. We feel until
you get the rib out, you haven’t really treated anything. I would
probably agree to lysis for a big, uncomfortable dominant arm in
the acute setting, but for those with subacute and chronic throm-
boses, after thombolysis, within weeks they re-occlude again, so
anticoagulation and getting to a rib resection is critical.
As far as doing more “selective” venograms postoperatively,
that might be something we could look at and is an excellent point
we could follow up on; however, we feel fairly confident that the
2-week time point for the venogram really lets us know who can
and does not have to go on further anticoagulation therapies.
We think that is a very valuable part of our algorithm, and if
stenosis is encountered, we can balloon, and they do well.
Often-times, their anticoagulation duration is reduced as well
because of that venogram.Thank you all very much.
